Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VPO 227

Next Previous
Drug Profile

VPO 227

Alternative Names: BPO-27; VPO-227

Latest Information Update: 28 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of California at San Francisco
  • Developer Vanda Pharmaceuticals
  • Class Antibacterials; Antidiarrhoeals; Carboxylic acids; Halogenated hydrocarbons; Heterocyclic compounds with 4 or more rings; Ketones; Oxazines; Pyrimidines; Pyrroles; Small molecules; Urologics
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cholera
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cholera
  • No development reported Diarrhoea; Polycystic kidney disease

Most Recent Events

  • 28 Jun 2025 No recent reports of development identified for preclinical development in Diarrhoea in USA (Intraperitoneal, Injection)
  • 28 Jun 2025 No recent reports of development identified for preclinical development in Polycystic-kidney-disease in USA (Intraperitoneal, Injection)
  • 31 Jul 2024 Vanda Pharmaceuticals receives approval for phase I trial for Cholera in Bangladesh before July 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top